Tetracycline-spironolactone formulation; a team play

• In: SIG: Individualised Medicine - Posters
• At: Basel (Switzerland) (2008)
• Type: Poster
• Poster code: IM-P-002
• By: SER, Filip (City Departement for Skin and Veneral Dieases, Belgrade, Yugoslavia)
• Co-author(s): Petronijevic, Dragoslav (PHARMACY BELGRADE, BELGRADE, Serbia)
  Gajdas, Mirjana (PHARMACY BELGRADE, BELGRADE, Serbia)
  Stojsic, Radmila (PHARMACY BELGRADE, BELGRADE, Serbia)
  Muzdeka, Nada (PHARMACY BELGRADE, BELGRADE, Serbia)
  Sarenac, Svetlana (PHARMACY BELGRADE, BELGRADE, Serbia)
  
• Abstract:

  Spironolactone was originally developed in the early 1970's as a competitive antagonist of aldosterone for the treatment of hyperaldosteronism, edema and hypokalemia. Topical spironolactone can act as an anti-androgen in human sebaceous glands, competing with dihydrotestosterone - DHT receptors and producing a decrease of labeled DHT. Applied..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login